What were the most common adverse events in the MOVe-OUT phase 3 trial of the use of molnupiravir for oral treatment of COVID-19?
Nausea, dizziness and diarrhea were the most commonly reported adverse events in the molnupiravir treated group.
Bernal AJ et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. NEJM. Published online 16 December 2021. DOI: 10.1056/NEJMoa2116044
Posted in Question Of The Day